In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 891-898

  Fiori, Pier Luigi ^a   Mattana, Antonella ^a   Dessì, Daniele ^a   Conti, Stefania ^b   Magliani, Walter ^b   Polonelli, Luciano ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Acanthamoeba; Anti idiotypic antibodies; Antibody derived peptides; Antimicrobial peptides; Killer toxins

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; BETA 1,6 GLUCAN; ENDO 1,3 BETA GLUCANASE; LAMINARAN; MONOCLONAL ANTIBODY; SYNTHETIC PEPTIDE;

ACANTHAMOEBA CASTELLANII; AMEBIASIS; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL KILLING; CELL MEMBRANE; CONTACT LENS; CONTROLLED STUDY; DRUG PROTEIN BINDING; GROWTH INHIBITION; HOST CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INCUBATION TIME; INFECTION PREVENTION; NONHUMAN; PROTEIN HYDROLYSIS; RECEPTOR BINDING; TROPHOZOITE;

ACANTHAMOEBA CASTELLANII; AMEBICIDES; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BETA-GLUCANS; CELL WALL; CONTACT LENSES; MICE; MYCOTOXINS; OLIGOPEPTIDES; POLYSACCHARIDES;

EID: 33645809751     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl051     Document Type: Article

References (46)

1. Visvesvara GS. Free-living pathogenic amoebae. In: Lennette EH, Hausler WJ, Truant JP, eds. Manual of Clinical Microbiology, 3rd edn. Washington, DC: American Society for Microbiology, 1980; 704-8.
2. Martinez AJ, Visvesvara GS. Free-living, amphizoic and opportunistic amebas. Brain Pathol 1997; 7: 583-98.
3. Hay J, Seal DV. Acanthamoeba keratitis: Risk factors and outcome. Br J Ophthalmol 1996; 80: 773-4.
4. Marciano-Cabral F, Puffenbarger R, Cabral GA. The increasing importance of Acanthamoeba infections. J Eukaryot Microbiol 2000; 47: 29-36.
5. Driebe WT, Jr. Present status of contact lens-induced corneal infections. Ophthalmol Clin North Am 2003; 16: 485-94.
6. Khan NA. Pathogenesis of Acanthamoeba infections. Microb Pathog 2003; 34: 277-85.
7. Seal DV. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye 2003; 17: 893-905.
8. Feingold JM, Abraham J, Bilgrami S et al. Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. Bone Marrow Transplant 1998; 22: 297-300.
9. Rosenberg AS, Morgan MB. Disseminated acanthamoebiasis presenting as lobular panniculitis with necrotizing vasculitis in a patient with AIDS. J Cutan Pathol 2001; 28: 307-13.
10. Marciano-Cabral F, Cabral GA. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev 2003; 16: 273-307.
11. Carter WW, Gompf SG, Toney JF et al. Disseminated Acanthamoeba sinusitis in a patient with AIDS: A possible role for early antiretroviral therapy. AIDS Read 2004; 14: 41-9.
12. Lloyd D, Turner NA, Khunkitti W et al. Encystation in Acanthamoeba castellanii: Development of biocide resistance. J Eukaryot Microbiol 2001; 48: 11-16.
13. Khunkitti W, Lloyd D, Furr JR et al. Aspects of the mechanisms of action of biguanides on trophozoites and cysts of Acanthamoeba castellanii. J Appl Microbiol 1997; 82: 107-14.
14. Hargrave SL, McCulley JP, Husseini Z. Results of a trial of combined propamidine isethionate and neomycin therapy for Acanthamoeba keratitis. Brolene Study Group. Ophthalmology 1999; 106: 952-7.
15. Seal D, Hay J, Kirkness C et al. Successful medical therapy of Acanthamoeba keratitis with topical chlorhexidine and propamidine. Eye 1996; 10: 413-21.
16. Kosrirukvongs P, Wanachiwanawin D, Visvesvara GS. Treatment of Acanthamoeba keratitis with chlorhexidine. Ophthalmology 1999; 106: 798-802.
17. Seijo Martinez M, Gonzalez-Mediero G, Santiago P et al. Granulomatous amebic encephalitis in a patient with AIDS: Isolation of Acanthamoeba sp. group II from brain tissue and successful treatment with sulfadiazine and fluconazole. J Clin Microbiol 2000; 38: 3892-5.
18. Singhal T, Bajpai A, Kalra V etal. Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials. Pediatr Infect Dis J 2001; 20: 623-7.
19. Kumar R, Lloyd D. Recent advances in the treatment of Acanthamoeba keratitis. Clin Infect Dis 2002; 35: 434-41.
20. Mills R. Microbial keratitis, what's the preferred initial therapy? View 1: Corneal scraping and combination antibiotic therapy is indicated. Br J Ophthalmol 2003; 87: 1167-9.
21. Schuster FL, Visvesvara GS. Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas. J Eukaryot Microbiol 1998; 45: 612-8.
22. Polonelli L, Lorenzini R, De Bernardis F et al. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand J Immunol 1993; 37: 105-10.
23. Polonelli L, De Bernardis F, Conti S et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 1994; 152: 3175-82.
24. Polonelli L, De Bernadis F, Conti S et al. Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 1996; 156: 1880-5.
25. Polonelli L, Séguy N, Conti S et al. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin Diagn Lab Immunol 1997; 4: 142-6.
26. Magliani W, Conti S, De Bernardis F et al. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat Biotechnol 1997; 15: 155-8.
27. Séguy N, Polonelli L, Dei-Cas E et al. Monoclonal killer toxin-like antiidiotypic antibodies to control rat-pneumocystosis. J Eukaryot Microbiol 1997; 44, 37S.
28. Conti S, Fanti F, Magliani W et al. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis 1998; 177: 807-11.
29. Conti S, Magliani W, Arseni S et al. In vitro activity of monoclonal and recombinant yeast killer toxin-like antibodies against antibiotic-resistant gram-positive cocci. Mol Med 2000; 6: 613-9.
30. Conti S, Magliani W, Arseni S et al. Inhibition by yeast killer toxin-like antibodies of oral streptococci adhesion to tooth surfaces in an ex vivo model. Mol Med 2002; 8: 313-7.
31. Cenci E, Mencacci A, Spreca A et al. Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun 2002; 70: 2375-82.
32. Savoia D, Avanzini C, Conti S et al. In vitro leishmanicidal activity of a monoclonal antibody mimicking a yeast killer toxin. J Eukaryot Microbiol 2002; 49: 319-23.
33. Cassone A, Conti S, De Bernardis F et al. Antibodies, killer toxins and antifungal immunoprotection: A lesson from nature? Immunol Today 1997; 18: 164-9.
34. Conti S, Magliani W, Gerloni M et al. A transphyletic anti-infectious control strategy based on the killer phenomenon. FEMS Immunol Med Microbiol 1998; 22: 151-61.
35. Magliani W, Conti S, Arseni S et al. Killer anti-idiotypes in the control of fungal infections. Curr Opin Investig Drug 2001; 2: 477-9.
36. Magliani W, Conti S, Cassone A et al. New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med 2002; 8: 121-6.
37. Beninati C, Oggioni MR, Boccanera M et al. Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol 2000; 18: 1060-4.
38. Polonelli L, Magliani W, Conti S et al. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 2003; 71: 6205-12.
39. Cenci E, Bistoni F, Mencacci A et al. A synthetic peptide as a novel anticryptococcal agent. Cell Microbiol 2004; 6: 953-61.
40. Travassos LR, Silva LS, Rodrigues EG et al. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J Antimicrob Chemother 2004; 54: 956-8.
41. Guyard C, Dehecq E, Tissier JP et al. Involvement of β-glucans in the wide-spectrum antimicrobial activity of Williopsis saturnus var. mrakii MUCL 41968 killer toxin. Mol Med 2002; 8: 686-94.
42. Garcia LS, Bruckner DA. Diagnostic Medical Parasitology, 2nd edn. Washington, DC: American Society for Microbiology, 1993; 601-5.
43. Mattana A, Cappai V, Alberti L et al. ADP and other metabolites released from Acanthamoeba castellanii lead to human monocytic cell death through apoptosis and stimulate the secretion of pro-inflammatory cytokines. Infect Immun 2002; 70: 4424-32.
44. Mattana A, Biancu G, Alberti L et al. In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acantahamoeba castellani. Antimicrob Agents Chemother 2004; 48: 4520-7.
45. Potter JL, Weisman RA. Differentiation in Acanthamoeba: β-glucan synthesis during encystment. Biochim Biophys Acta 1971; 237: 65-74.
46. 14C)glucose into alkali-soluble and insoluble β-glucans by glucose 6-phosphate and related compounds. Biochim Biophys Acta 1976; 428: 240-52.